Eye Health News and Research

Latest Eye Health News and Research

On the campaign trail, Santorum hits Romney on Mass. health law

GOP Presidential hopeful Rick Santorum continued to press the parallels between the state law signed by his rival, former Massachusetts Gov. Mitt Romney, and the federal measure, as well as to question Romney's explanation of his positions. Meanwhile, news outlets report on how the gender gap and social issues like contraception are playing in this election cycle.

9 Mar 2012

Infrared optical head tracker can help diagnose ocular torticollis

Wii remotes are not all about fun and games. Scientists can use them to assess and diagnose children with an abnormal head position caused by eye diseases. As described in a recent Investigative Ophthalmology & Visual Science article, researchers developed a low-cost digital head posture measuring device with Nintendo Wiimotes to help diagnose this condition, medically called ocular torticollis.

9 Mar 2012

Genetically modified pig may hold keys to develop treatments for RP

A newly developed, genetically modified pig may hold the keys to the development of improved treatments and possibly even a cure for retinitis pigmentosa (RP), the most common inherited retinal disease in the United States.

9 Mar 2012

Biologists identify how and where the brain processes FM sweeps

In both animals and humans, vocal signals used for communication contain a wide array of different sounds that are determined by the vibrational frequencies of vocal cords. For example, the pitch of someone's voice, and how it changes as they are speaking, depends on a complex series of varying frequencies. Knowing how the brain sorts out these different frequencies-which are called frequency-modulated (FM) sweeps-is believed to be essential to understanding many hearing-related behaviors, like speech.

9 Mar 2012

Avedro submits VibeX/KXL System NDA with FDA to treat keratoconus, corneal ectasia

Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.

9 Mar 2012

Get ready for Be Medicinewise Week 2012

Building on the success of last year’s inaugural event, the week will urge all Australians to stop, think and learn more about the medicines they are using and encourage them to seek information to make better decisions about their health.

8 Mar 2012

Cancer-based blood vessel theory questioned

Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).

8 Mar 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012

Children with autism look away from faces when thinking

Children with autism look away from faces when thinking, especially about challenging material, according to new research from Northumbria University.

8 Mar 2012

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Blocking Plexin B1 protein can prevent formation of breast cancer metastases

In particularly aggressive forms of breast cancer, cancer cells can settle in other organs and form metastases there. Once such metastases form, complete recovery is rare. Consequently, it is enormously important to prevent the metastasisation of the breast cancer cells. The success, however, achieved by using existing forms of therapy is limited.

6 Mar 2012

Ivantis initiates enrollment in Hydrus Microstent study for open angle glaucoma

Ivantis announced the enrollment of the first patient in the Hydrus IV study today. The Hydrus Microstent is the world's first intracanalicular scaffold for treatment of primary open angle glaucoma, a disease that afflicts over 70 million people worldwide and approximately 3 million people in the United States.

6 Mar 2012

AMA details concerns about payment policy changes for Medicare Part C, D

Modern Healthcare details the positions taken by the American Medical Association in response to recent changes proposed by the Centers for Medicare & Medicaid Services. Also, in related news, a new panel sets to work on improving the physician payment system.

6 Mar 2012

Almost 70% of young adults with Asperger syndrome have suffered from depression

Given that almost 70% of young adults with Asperger syndrome have suffered from depression, it is vital that psychiatric care staff are aware of this so that patients are given the right treatment, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

6 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

Scientists successfully cultivate stem cells on human corneas

A new cornea may be the only way to prevent a patient going blind - but there is a shortage of donated corneas and the queue for transplantation is long. Scientists at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have for the first time successfully cultivated stem cells on human corneas, which may in the long term remove the need for donators.

5 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012